Is SAPHO Syndrome the Adult Form of CRMO? Explained

SAPHO syndrome is not simply the adult form of chronic recurrent multifocal osteomyelitis (CRMO), although the two conditions are very closely related. They are both part of the same spectrum of autoinflammatory bone diseases, conditions believed to involve immune-system dysregulation where inflammation occurs in the bone without an infection (sterile osteitis) ^{[1] [2]}. While the term CRMO is most commonly used to describe the condition when it appears in children, and SAPHO is more often diagnosed in adults with specific skin and chest-wall symptoms, these are not strictly age-defined separate diseases ^{[3] [4]}. Today, many experts group them together as overlapping presentations within the broader category of Chronic Nonbacterial Osteitis (CNO), though terminology is not universally standardized ^{[1] [5]}.

Making Sense of the Terminology

Patients often encounter the terms CRMO, adult CNO, and SAPHO, which can be confusing. Here is how medical experts generally use these labels:

• CRMO (Chronic Recurrent Multifocal Osteomyelitis): This term is traditionally used for children and adolescents who develop chronic, sterile bone inflammation in multiple sites ^{[3] [5]}. It is the most common label in pediatric rheumatology for this spectrum of disease.
• Adult CNO (Chronic Nonbacterial Osteitis): Recently, medical consensus groups have proposed “adult CNO” as a useful umbrella term for adults experiencing this same spectrum of sterile bone inflammation ^{[1] [5]}.
• SAPHO Syndrome: This is an acronym for Synovitis (inflammation around a joint), Acne, Pustulosis (pus-filled skin bumps), Hyperostosis (excess bone growth), and Osteitis (bone inflammation). It describes a characteristic combination of joint/bone symptoms and skin conditions. While most commonly diagnosed in adults, children can also develop SAPHO ^{[4] [6]}. Because SAPHO falls under the same biological spectrum, adult CNO is increasingly used as a broader category that includes SAPHO phenotypes, though some doctors still prefer the SAPHO label ^{[1] [2]}.

Differences in Presentation

While CRMO and SAPHO share overlapping features, their pathophysiology is incompletely understood. They are believed to share similar immune system dysregulation, but there are differences in how they typically present ^{[4] [7]}:

• Bone Locations: In adults (often labeled as SAPHO or adult CNO), the inflammation most frequently targets the anterior chest wall, specifically the sternoclavicular joints (where the collarbone meets the breastbone) ^{[8] [9]}. In children with CRMO, bone lesions are more commonly found in the long bones of the legs or the collarbones. However, both age groups can experience inflammation in the spine, pelvis, or jaw ^{[10] [4]}.
• Skin Involvement: A hallmark of SAPHO is the presence of skin conditions, most notably palmoplantar pustulosis (recurrent sterile pustules or pus-filled bumps, often with redness and scaling, on the palms and soles) or severe acne ^{[11] [12]}. Skin issues are not mandatory for a diagnosis; bone and skin symptoms can appear years apart, or skin symptoms may never develop ^{[13] [14]}. Children with CRMO can also develop these skin issues, though they are reported less frequently in pediatric groups ^{[10] [12]}.

Diagnostic Safety

Because sterile osteitis means that inflammation is happening without an infection, doctors must first rule out other causes of bone pain or lesions, including infections, fractures, and malignancies ^[5]. This may require blood tests, imaging like whole-body MRI, and sometimes a bone biopsy or cultures ^[5]. You should not self-diagnose a painful bone lesion based on symptoms alone. If you experience new fever, rapidly worsening pain, redness, or swelling, seek prompt medical assessment.

Does the Label Change Your Treatment?

The exact label your doctor uses—whether SAPHO, CRMO, or adult CNO—does not entirely dictate your treatment plan ^[4]. Doctors individualize treatment based on the severity of your specific symptoms, affected locations, and any associated conditions.

Treatment decisions are primarily driven by:

• Symptom Severity: First-line treatments often start with nonsteroidal anti-inflammatory drugs (NSAIDs) to manage pain and inflammation ^{[1] [15]}. NSAIDs should be taken only as directed, should not be combined with other NSAIDs, and carry risks for individuals with kidney disease, a history of stomach ulcers or bleeding, cardiovascular conditions, or pregnancy.
• Bone Risk and Spinal Involvement: Inflammation in high-risk areas, such as the spine, warrants prompt specialist assessment ^{[15] [16]}. Depending on imaging, structural damage, and symptoms, doctors may prescribe more aggressive off-label treatments like bisphosphonates (medicines that alter bone breakdown) or biologic drugs (targeted immune system medicines) ^{[15] [16]}. Seek urgent medical care if you develop new weakness, numbness, difficulty walking, or bowel/bladder changes, as these can be red flags for spinal complications.
• Associated Skin or Gut Conditions: If you have extraosseous symptoms (symptoms outside the bone, like severe acne, pustulosis, or inflammatory bowel disease), treatment must be carefully coordinated between rheumatologists, dermatologists, and gastroenterologists ^{[1] [17]}. While one biologic medicine may sometimes address more than one problem, responses vary, and a drug that helps the bone may not help the skin or gut (or vice versa) ^{[18] [19]}.

Ultimately, while terminology may vary between clinics, your care team will tailor your treatment to your individual needs rather than relying solely on the disease label.